CN103945867B - 针对iNKT的人类化抗体 - Google Patents

针对iNKT的人类化抗体 Download PDF

Info

Publication number
CN103945867B
CN103945867B CN201280053174.3A CN201280053174A CN103945867B CN 103945867 B CN103945867 B CN 103945867B CN 201280053174 A CN201280053174 A CN 201280053174A CN 103945867 B CN103945867 B CN 103945867B
Authority
CN
China
Prior art keywords
antibody
cells
human
inkt
nktt120
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280053174.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103945867A (zh
Inventor
阿列姆塞盖德·特鲁内
弗兰西斯·约瑟夫·卡尔
蒂莫西·戴维·琼斯
詹姆斯·P·格雷格森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NKT Therapeutics Inc
Original Assignee
NKT Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NKT Therapeutics Inc filed Critical NKT Therapeutics Inc
Publication of CN103945867A publication Critical patent/CN103945867A/zh
Application granted granted Critical
Publication of CN103945867B publication Critical patent/CN103945867B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201280053174.3A 2011-10-27 2012-10-26 针对iNKT的人类化抗体 Expired - Fee Related CN103945867B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552337P 2011-10-27 2011-10-27
US61/552,337 2011-10-27
PCT/US2012/062124 WO2013063395A1 (en) 2011-10-27 2012-10-26 Humanized antibodies to inkt

Publications (2)

Publication Number Publication Date
CN103945867A CN103945867A (zh) 2014-07-23
CN103945867B true CN103945867B (zh) 2018-01-02

Family

ID=48168549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280053174.3A Expired - Fee Related CN103945867B (zh) 2011-10-27 2012-10-26 针对iNKT的人类化抗体

Country Status (13)

Country Link
US (1) US9932402B2 (enExample)
EP (1) EP2755688A4 (enExample)
JP (1) JP2015502340A (enExample)
KR (1) KR20140093964A (enExample)
CN (1) CN103945867B (enExample)
AU (1) AU2012328588C1 (enExample)
BR (1) BR112014009962A2 (enExample)
CA (1) CA2853719A1 (enExample)
HK (2) HK1199405A1 (enExample)
IL (1) IL232017A0 (enExample)
RU (1) RU2014120694A (enExample)
SG (1) SG11201401319XA (enExample)
WO (1) WO2013063395A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271629A1 (en) * 2013-03-14 2014-09-18 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
WO2015069697A2 (en) * 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
AU2015204674B2 (en) * 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
EP3104864A1 (en) * 2014-02-14 2016-12-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3190415B1 (en) * 2014-07-25 2019-05-01 Riken Memory invariant nkt cell marker
US20160022777A1 (en) * 2014-07-28 2016-01-28 Nkt Therapeutics Inc. Combination therapy with il-12
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
EP3383412A4 (en) 2015-12-02 2019-06-05 Stcube, Inc. SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF
KR20180130541A (ko) 2016-03-29 2018-12-07 주식회사 에스티큐브앤컴퍼니 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
CN109715666B (zh) 2016-07-20 2023-02-21 斯特库比股份有限公司 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
CN109923126B (zh) * 2016-09-16 2022-06-03 上海复宏汉霖生物技术股份有限公司 抗-pd-1抗体
CN113508137B (zh) * 2019-01-29 2024-12-20 上海交通大学 一种嵌合抗原受体及其应用
CA3173325A1 (en) * 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof
JP2023522979A (ja) * 2020-04-23 2023-06-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉＮＫＴ細胞の活性化による老化細胞の排除
WO2022187141A1 (en) 2021-03-01 2022-09-09 Deciduous Therapeutics Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
AU7482696A (en) 1995-11-01 1997-05-22 Genetics Institute Inc. Methods for administration of il-12
WO1999034209A1 (en) 1997-12-31 1999-07-08 The Brigham And Women's Hospital, Inc. DIAGNOSTIC AND THERAPEUTIC METHODS BASED UPON Vα24JαQ T CELLS
ES2389645T3 (es) 2000-06-19 2012-10-30 Beth Israel Deaconess Medical Center Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T
CA2454048C (en) * 2001-07-17 2011-05-03 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
JP4689268B2 (ja) 2002-06-14 2011-05-25 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｉｌ−１３およびｎｋ−ｔ細胞に関する、結腸炎を処置および予防する方法
US9809654B2 (en) * 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
AU2005280163B2 (en) * 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
ES2378076T3 (es) * 2004-11-02 2012-04-04 The Board Of Trustees Of Leland Stanford Junior University Métodos para la inhibición de células NKT
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008140487A2 (en) 2006-11-14 2008-11-20 Elusys Therapeutics, Inc. Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US8012484B2 (en) 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
US20090028849A1 (en) * 2007-07-24 2009-01-29 O'brien Rebecca L Agents and methods for inhibition of airway hyperresponsiveness
WO2009026412A1 (en) 2007-08-21 2009-02-26 Children's Medical Center Corporation Treatment of airway hyperreactivity
EP2222700A2 (en) 2007-11-27 2010-09-01 Medtronic, Inc. Humanized anti-amyloid beta antibodies
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
CA2792754C (en) 2010-03-12 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services .beta.-mannosylceramide and stimulation of nkt cell anti-tumor immunity
WO2011149881A2 (en) 2010-05-24 2011-12-01 Children's Medical Center Corporation Methods for the treatment and prevention of inflammatory diseases
WO2013079687A1 (en) 2011-11-30 2013-06-06 The Chancellor, Masters And Scholars Of The University Of Oxford Inkt cell modulators and methods of using the same
WO2015069697A2 (en) 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
US20160022777A1 (en) 2014-07-28 2016-01-28 Nkt Therapeutics Inc. Combination therapy with il-12

Also Published As

Publication number Publication date
US20130136735A1 (en) 2013-05-30
AU2012328588B2 (en) 2015-07-09
JP2015502340A (ja) 2015-01-22
CA2853719A1 (en) 2013-05-02
SG11201401319XA (en) 2014-06-27
AU2012328588C1 (en) 2015-12-03
HK1199837A1 (en) 2015-07-24
KR20140093964A (ko) 2014-07-29
EP2755688A4 (en) 2014-08-06
BR112014009962A2 (pt) 2019-09-24
HK1199405A1 (en) 2015-07-03
CN103945867A (zh) 2014-07-23
US9932402B2 (en) 2018-04-03
EP2755688A1 (en) 2014-07-23
WO2013063395A1 (en) 2013-05-02
IL232017A0 (en) 2014-05-28
AU2012328588A1 (en) 2014-04-24
RU2014120694A (ru) 2015-12-10

Similar Documents

Publication Publication Date Title
CN103945867B (zh) 针对iNKT的人类化抗体
US20210301028A1 (en) Composition and methods for anti-tnfr2 antibodies
US20230340114A1 (en) Novel anti-lilrb4 antibodies and derivative products
EP3993876B1 (en) Anti-cd154 antibodies and uses thereof
KR101197542B1 (ko) 항-ｃｄ20 항체 및 이용 방법
AU2006244445B2 (en) Anti-CD19 antibody therapy for autoimmune disease
US9574000B2 (en) Anti-human B7-H4 antibodies and their uses
RU2691428C2 (ru) Антитела к h7cr
US20240059781A1 (en) Methods of inducing immune tolerance with modified anti-cd154 antibodies
US20200181270A1 (en) Methods and compositions for treating systemic mastocytosis
CN107922501A (zh) 抗cd40抗体用于治疗狼疮性肾炎的用途
JP2020535819A (ja) Ｃｄ３／ｃｄ３３二重特異性結合分子
US11795228B2 (en) Anti-CD94 antibodies and methods of use thereof
JP2024535124A (ja) 破傷風毒素に結合する抗体およびその使用
US20230400467A1 (en) Pvrl2 and/or pvrig as biomarkers for treatment
US20250197505A1 (en) Anti-cd94 antibodies and methods of use thereof
AU2017235959A1 (en) Humanized antibodies to iNKT
US20240082397A1 (en) Anti-pvrig antibodies formulations and uses thereof
HK40074747B (en) Anti-cd154 antibodies and uses thereof
HK40074747A (en) Anti-cd154 antibodies and uses thereof
EA040553B1 (ru) Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1199405

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180102

Termination date: 20181026

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1199405

Country of ref document: HK